MX2010002890A - 1, 2, 3-triacin -4-onas sustituidas en la posicion 3 y 1, 3- pirimidinonas sustituidas en la posicion 3 para mejorar las respuestas sinapticas glutamatergicas. - Google Patents
1, 2, 3-triacin -4-onas sustituidas en la posicion 3 y 1, 3- pirimidinonas sustituidas en la posicion 3 para mejorar las respuestas sinapticas glutamatergicas.Info
- Publication number
- MX2010002890A MX2010002890A MX2010002890A MX2010002890A MX2010002890A MX 2010002890 A MX2010002890 A MX 2010002890A MX 2010002890 A MX2010002890 A MX 2010002890A MX 2010002890 A MX2010002890 A MX 2010002890A MX 2010002890 A MX2010002890 A MX 2010002890A
- Authority
- MX
- Mexico
- Prior art keywords
- syndrome
- disorders
- substituted
- treatment
- sleep apnea
- Prior art date
Links
- -1 3-substituted 1,2,3-triazin-4-one Chemical class 0.000 title 1
- 230000002708 enhancing effect Effects 0.000 title 1
- 230000000848 glutamatergic effect Effects 0.000 title 1
- 230000009782 synaptic response Effects 0.000 title 1
- 210000004556 brain Anatomy 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 230000029058 respiratory gaseous exchange Effects 0.000 abstract 3
- 208000003417 Central Sleep Apnea Diseases 0.000 abstract 2
- 208000019022 Mood disease Diseases 0.000 abstract 2
- 208000004756 Respiratory Insufficiency Diseases 0.000 abstract 2
- 206010038678 Respiratory depression Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 206010010356 Congenital anomaly Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 206010013647 Drowning Diseases 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 206010021133 Hypoventilation Diseases 0.000 abstract 1
- 108010025020 Nerve Growth Factor Proteins 0.000 abstract 1
- 102000007072 Nerve Growth Factors Human genes 0.000 abstract 1
- 208000004166 Obesity Hypoventilation Syndrome Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 206010035004 Pickwickian syndrome Diseases 0.000 abstract 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 abstract 1
- 208000006289 Rett Syndrome Diseases 0.000 abstract 1
- 208000034972 Sudden Infant Death Diseases 0.000 abstract 1
- 206010042440 Sudden infant death syndrome Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 230000003444 anaesthetic effect Effects 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 229940125717 barbiturate Drugs 0.000 abstract 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 abstract 1
- 230000006399 behavior Effects 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 230000003930 cognitive ability Effects 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 206010027175 memory impairment Diseases 0.000 abstract 1
- 210000005036 nerve Anatomy 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 239000003900 neurotrophic factor Substances 0.000 abstract 1
- 208000001797 obstructive sleep apnea Diseases 0.000 abstract 1
- 229940127240 opiate Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 201000002859 sleep apnea Diseases 0.000 abstract 1
- 208000020431 spinal cord injury Diseases 0.000 abstract 1
- 210000000225 synapse Anatomy 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Esta invención se relaciona con compuestos, composiciones farmacéuticas y métodos para utilizarse en la prevención y tratamiento de la insuficiencia cerebral, incluyendo la mejora del funcionamiento del receptor en las sinapsis en las redes cerebrales, responsables de los comportamientos básicos y de orden superior. Estas redes cerebrales, que están involucradas en la regulación de la respiración y las capacidades cognoscitivas relacionadas con el daño de la memoria, tal como se observa en una variedad de demencias, en desequilibrios en la actividad neuronal entre diferentes regiones cerebrales, como se sugiere en los trastornos tales como la enfermedad de Parkinson, esquizofrenia, depresión respiratoria, apneas del sueño, trastorno de déficit de atención e hiperactividad y trastornos efectivos o del ánimo, y en trastornos en donde está implicada una deficiencia en los factores neurotróficos, asi como en trastornos de la respiración, tales como sobredosis del alcohol, un opiáceo, un opioide, un barbitúrico, un anestésico o una toxina nerviosa, o en donde la depresión respiratoria resulta de una condición médica tal como apnea del sueño central, apnea del sueño central inducida por apoplejía, apnea del sueño obstructiva, síndrome congénito de hipoventilación, síndrome de hipoventilación por obesidad, síndrome de muerte infantil súbita, síndrome de Rett, lesión de la médula espinal, lesión traumática del cerebro, respiración de Cheney-Stokes, maldición de Ondina, Síndrome de Prader-Willis y ahogamiento. En un aspecto particular, la invención se relaciona con compuestos útiles para el tratamiento de tales condiciones y con métodos para utilizar estos compuestos para tal tratamiento.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99454807P | 2007-09-20 | 2007-09-20 | |
| PCT/US2008/010877 WO2009038752A2 (en) | 2007-09-20 | 2008-09-19 | 3-substituted 1,2,3-triazin-4-one's and 3-substituted 1,3-pyrimidinone's for enhancing glutamatergic synaptic responses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010002890A true MX2010002890A (es) | 2010-07-02 |
Family
ID=40468690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010002890A MX2010002890A (es) | 2007-09-20 | 2008-09-19 | 1, 2, 3-triacin -4-onas sustituidas en la posicion 3 y 1, 3- pirimidinonas sustituidas en la posicion 3 para mejorar las respuestas sinapticas glutamatergicas. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20100267728A1 (es) |
| EP (1) | EP2195303A4 (es) |
| JP (1) | JP2010540436A (es) |
| KR (1) | KR20100063087A (es) |
| CN (1) | CN101801939A (es) |
| AU (1) | AU2008301884B2 (es) |
| BR (1) | BRPI0815957A2 (es) |
| CA (1) | CA2700158A1 (es) |
| EA (1) | EA201000516A1 (es) |
| MX (1) | MX2010002890A (es) |
| NZ (1) | NZ584098A (es) |
| WO (1) | WO2009038752A2 (es) |
| ZA (1) | ZA201002016B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2144506T3 (da) * | 2007-01-03 | 2012-03-05 | Servier Lab | 3-substitueret [1,2,3]-benzotriazinonforbindelse til at fremme glutamaterge synaptiske responser |
| BRPI0720323A2 (pt) * | 2007-01-03 | 2016-08-09 | Cortex Pharma Inc | composto, método de tratamento, composição farmacêutica e uso do composto |
| EA200901546A1 (ru) | 2007-05-17 | 2010-04-30 | Кортекс Фармасеутикалс, Инк. | Дизамещенные амиды для усиления глутаматергических синаптических ответов |
| US8168632B2 (en) | 2007-08-10 | 2012-05-01 | Cortex Pharmaceuticals, Inc. | Bicyclic amide derivatives for the treatment of respiratory disorders |
| BRPI0823262A2 (pt) | 2007-08-10 | 2013-09-24 | Cortex Pharma Inc | mÉtodo de tratamento de depressço respiratària e uso de um composto na fabricaÇço de um medicamento para o tratamento de depressço respiratària |
| US20110257186A1 (en) * | 2010-04-15 | 2011-10-20 | Staubli Ursula V | Compositions and methods for treating visual disorders |
| FR3019464B1 (fr) * | 2014-04-07 | 2016-05-06 | Servier Lab | Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent |
| CN106226509B (zh) * | 2016-08-12 | 2019-09-06 | 中国人民解放军第四军医大学 | 一种在小鼠前扣带回皮层诱发dse现象的方法 |
| GB201702221D0 (en) | 2017-02-10 | 2017-03-29 | Univ Of Sussex | Compounds |
| CN108084104A (zh) * | 2017-12-27 | 2018-05-29 | 温州大学 | 1，2，3-苯并三嗪-4（3h）-酮化合物的合成方法 |
| GB201803340D0 (en) | 2018-03-01 | 2018-04-18 | Univ Of Sussex | Compounds |
| CN116005178B (zh) * | 2023-01-28 | 2023-07-18 | 淮北师范大学 | 一种1,2-二氢喹唑啉类化合物的合成方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5776935A (en) * | 1996-07-25 | 1998-07-07 | Merz & Co. Gmbh & Co. | Pyrido-phtalazin diones and their use against neurological disorders associated with excitotoxicity and malfunctioning of glutamatergic neurotransmission |
| DE19900544A1 (de) * | 1999-01-11 | 2000-07-13 | Basf Ag | Verwendung von Verbindungen der Formel I zur Prophylaxe und Therapie der zerebralen Ischämie |
| CA2583158A1 (en) * | 2004-10-13 | 2006-04-27 | Amgen Inc. | Triazoles and their use as bradykinin b1 receptor antagonists |
| BRPI0720323A2 (pt) * | 2007-01-03 | 2016-08-09 | Cortex Pharma Inc | composto, método de tratamento, composição farmacêutica e uso do composto |
-
2008
- 2008-09-19 MX MX2010002890A patent/MX2010002890A/es active IP Right Grant
- 2008-09-19 EP EP08831417A patent/EP2195303A4/en not_active Withdrawn
- 2008-09-19 CN CN200880107960A patent/CN101801939A/zh active Pending
- 2008-09-19 CA CA2700158A patent/CA2700158A1/en not_active Abandoned
- 2008-09-19 EA EA201000516A patent/EA201000516A1/ru unknown
- 2008-09-19 AU AU2008301884A patent/AU2008301884B2/en not_active Expired - Fee Related
- 2008-09-19 JP JP2010525829A patent/JP2010540436A/ja active Pending
- 2008-09-19 WO PCT/US2008/010877 patent/WO2009038752A2/en not_active Ceased
- 2008-09-19 US US12/733,822 patent/US20100267728A1/en not_active Abandoned
- 2008-09-19 KR KR1020107006440A patent/KR20100063087A/ko not_active Withdrawn
- 2008-09-19 BR BRPI0815957A patent/BRPI0815957A2/pt not_active IP Right Cessation
- 2008-09-19 NZ NZ584098A patent/NZ584098A/en not_active IP Right Cessation
-
2010
- 2010-03-19 ZA ZA2010/02016A patent/ZA201002016B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2700158A1 (en) | 2009-03-26 |
| EA201000516A1 (ru) | 2010-10-29 |
| ZA201002016B (en) | 2010-12-29 |
| WO2009038752A2 (en) | 2009-03-26 |
| WO2009038752A3 (en) | 2009-07-09 |
| EP2195303A4 (en) | 2011-07-20 |
| KR20100063087A (ko) | 2010-06-10 |
| CN101801939A (zh) | 2010-08-11 |
| JP2010540436A (ja) | 2010-12-24 |
| AU2008301884A1 (en) | 2009-03-26 |
| NZ584098A (en) | 2012-05-25 |
| BRPI0815957A2 (pt) | 2019-09-24 |
| EP2195303A2 (en) | 2010-06-16 |
| AU2008301884B2 (en) | 2012-12-20 |
| US20100267728A1 (en) | 2010-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009012430A (es) | Amidas disustituidas para mejorar las respuestas sinapticas glutamatergicas. | |
| MX2010002890A (es) | 1, 2, 3-triacin -4-onas sustituidas en la posicion 3 y 1, 3- pirimidinonas sustituidas en la posicion 3 para mejorar las respuestas sinapticas glutamatergicas. | |
| SG163526A1 (en) | Bicyclic amides for enhancing glutamatergic synaptic responses | |
| MX2009004071A (es) | Moduladores de bifenilsulfonilo y fenil-heteroarilsulfonilo del receptor de histamina h3 utiles para el tratamiento de trastornos relacionados con los mismos. | |
| NO20082264L (no) | Histamin-3 reseptorantagonister | |
| WO2007088450A3 (en) | Chromane antagonist of the h-3 receptor | |
| CR20190563A (es) | Imidazopirimidinas diazabicíclicas sustituidas y su uso para el tratamiento de trastornos respitatorios | |
| Maso et al. | Sleep disturbance: a forgotten syndrome in patients with Chiari I malformation | |
| JOP20220102A1 (ar) | مثبطات المُسْتقبلة الأدرينِية adrac2 | |
| Inoue et al. | Efficacy and safety of pramipexole in Japanese patients with primary restless legs syndrome: A polysomnographic randomized, double-blind, placebo-controlled study | |
| JP2007513968A5 (es) | ||
| Giordano et al. | Obstructive sleep apnea in Prader-Willi syndrome: risks and advantages of adenotonsillectomy | |
| WO2008153958A3 (en) | Crystalline forms of (r)-1-{2-[4'- (3-methoxy-propane-1- sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto | |
| Boeve | Update on the diagnosis and management of sleep disturbances in dementia | |
| Malhotra et al. | Neurodegenerative disease and REM behavior disorder | |
| MX2011008060A (es) | Derivados de amida biciclica para mejorar las respuestas sinapticas glutamatergicas. | |
| NO20090972L (no) | Pyrazolo[1,5-A]pyrimidiner, fremgangsmater, anvendelser og sammensetninger | |
| BRPI0512567A (pt) | compostos antagonistas de receptor de histamina-3 diazabicìclico e respectivas composições farmacêuticas | |
| JP2008507550A5 (es) | ||
| Yerram et al. | Sleep Issues in Motor Neuron Diseases | |
| Noseda et al. | CPAP with algorithm-based versus titrated pressure: A randomized study | |
| Buysse et al. | Sleep and Sleep–Wake Disorders | |
| Park et al. | Insomnia in Parkinson’s disease | |
| Chow | Sleep in Parkinson's Disease | |
| Molano | Sleep in mild cognitive impairment and dementia. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |